Crizotinib CAS 877399-52-5 Assay ≥99.0% API Factory High Quality
Shanghai Ruifu Chemical Co., Ltd. ndiyo inotungamira kugadzira yeCrizotinib (CAS: 877399-52-5) ine mhando yepamusoro.Ruifu Chemical inogona kupa kutumirwa kwepasirese, mutengo wemakwikwi, sevhisi yakanakisa, idiki uye yakawanda huwandu huripo.Tenga Crizotinib,Please contact: alvin@ruifuchem.com
| Chemical Name | Crizotinib |
| Mashoko anoreva zvakafanana | Xalkori;PF-02341066;Crozotinib;Crizotinib Xalkori;3--[1-(2,6-Dichloro-3-Fluoro-phenyl)-ethoxy]-5-(1-Piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine;(R) -3- [1- (2,6-Dichloro-3-Fluorophenyl) ethoxy]-5-(1-Piperidin-4-yl-1H- pyrazol-4-yl)pyridin-2-ylamine |
| Nhamba yeCAS | 877399-52-5 |
| Stock Status | MuStock, Kugadzirwa Kunokwira Kusvika Mazana emaKilogram |
| Molecular Formula | C21H22Cl2FN5O |
| Molecular Weight | 450.34 |
| Melting Point | 192℃ |
| Density | 1.47±0.10 g/cm3 |
| Storage Temperature | Room Temperature |
| Origin | Shanghai, China |
| Brand | Ruifu Chemical |
| Item | Zvinotsanangurwa |
| Chitarisiko | Ichena kusvika kuOff-White Powder |
| Identification | By IR, HPLC |
| Kujeka Kwemhinduro | Conform to Standard |
| Kurasika paKuomesa | ≤1.00% |
| Residue paIgnition | ≤0.50% |
| Kusachena kwakabatana | (neHPLC) |
| Kusachena Kumwechete | ≤0.50% |
| Zvose Zvisina Kuchena | ≤1.00% |
| Heavy Metals | ≤20ppm |
| Assay | ≥99.0% |
| Residual Solvents | Sangana Nekutsanangurwa |
| Sherufu Hupenyu | 24 Mwedzi |
| Test Standard | Enterprise Standard |
Package:Bhodhoro, Aluminium foil bag, 25kg/Cardboard Drum, kana zvinoenderana nezvinodiwa nemutengi.
Storage Condition:Chengetedza mudziyo wakavharwa zvakasimba uye chengeta munzvimbo inotonhorera, yakaoma (2~8℃) uye inofefeterwa nemhepo yakanaka kure nezvinhu zvisingaenderane.Dzivirira kubva kuchiedza uye unyoro.
KutumiraKuendesa kupasirese nemhepo, neFedEx / DHL Express.Ipa kutumirwa nekukurumidza uye kwakavimbika.
Tsanangudzo Yekuchengetedza 24/25 - Dzivisa kusangana neganda nemeso.
UN IDs UN 3077 9 / PGIII
WGK Germany 3
HS Code 2933990099
Hazard Kirasi IRRITANT
Crizotinib (CAS 877399-52-5), (Crizotinib, Xalkori R), ine simba uye inosarudza ATP inokwikwidza diki molecule inhibitor yeALK uye c-Met.Muna Nyamavhuvhu 2011, iyo United States FDA yakabvumidza Crizotinib kuti irapwe anaplastic lymphoma kinase (ALK) yakarongazve isiri-diki-cell cancer yemapapu (NSCLC).Crizotinib ine mbiri ATP inokwikwidza inhibitor ye tyrosine kinases c-MET (Mesenchymal-Epithelial Transition Factor) kinase (cellular IC50 = 8 nM) uye ALK (cellular IC50 = 20 nM), zvose zviri zviviri zvakakosha zvinangwa zvekemotherapy kenza.Apo crizotinib yakaedzwa kusarudzwa kunopesana nemamwe kinases yakawanikwa iine enzyme IC50 mukati me100-fold multiples ye c-MET ye13 ye120 kinases yakaedzwa.Mune cellular assays, crizotinib yakawanikwa inhibit RON (recepteur d'origine nantais) kinase ine 10-fold selectivity window pamusoro peC-MET.
Crizotinib (PF-02341066) Crizotinib ine simba c-Met uye ALK inhibitor, iyo IC50 tsika mu cell assay yaive 11 nM uye 24 nM, zvichiteerana.Iyo zvakare inhibitor ine simba yeROS1 ine kukosha kweKi isingasviki 0.025 nM.Crizotinib inogona kukonzera autophagy mumhando dzakasiyana dzekenza yemapapu maseru nekuvharisa iyo STAT3 nzira.
Crizotinib ine simba uye inosarudza mbiri inhibitor ye mesenchymal-epithelial transition factor (c-MET) kinase uye anaplastic lymphoma kinase (ALK).Crizotinib inogona kuita antitumor agent.Muna Nyamavhuvhu 2011, iyo United States FDA yakabvumidza crizotinib kurapwa kweanaplastic lymphoma kinase (ALK) yakarongazve isiri-diki-cell cancer yemapapu (NSCLC).
Crizotinib (Xalkori (R), Pfizer), yakagamuchirwa muna 2011, ndiyo yekutanga yakabvumirwa inhibitor inotarisa anaplastic lymphoma kinase (ALK).ROS protooncogene 1-encoded kinase (ROS1) ye tyrosine kinase insulin receptor class uye MET proto-oncogene-encoded kinase yehepatocyte growth factor receptor (HGFR) kirasi ndiyo mamwe kinase anotarirwa ne crizotinib.Paakabvumirwa muna 2011, crizotinib yaiva yekutanga. mushonga wakanangana nevarwere veNSCLC.Zvisinei, kupikisa crizotinib kwaiwanzoonekwa mumwedzi inenge ye8 mushure mekutanga kushandiswa uye inopfuura hafu yevarwere vakabatwa nekrizotinib vakawana migumisiro yegumbo.Muna 2016, crizotinib yakawedzerwa kubvumidzwa kuROS1-positive NSCLC neFDA.
Crizotinib (Xalkori) inonzi oral receptor tyrosine kinase inhibitor inoratidzwa pakurapa varwere vane advanced or metastatic isiri-diki cell cell cancer cancer (NSCLC).Zvinowanzoitika mhedzisiro nekushandiswa kweXalkori zvinosanganisira hutachiona hwepamusoro hwekufema, kuda kurutsa, kurutsa, kurwadziwa mudumbu, kuderera kwechido, kushaya hope, dzungu, kunzwa kuneta, manyoka, kuvimbiswa, kuputika kana kuputika, zviratidzo zvekutonhora (kuzara mhino, kutsvedza, kurwadziwa kwehuro), kusanzwa kana kurira, kana kuzvimba mumaoko ako kana tsoka.
